-
-
Overview
-
Please contact us at for specific academic pricing.
Background
Teriflunomide (also known as A77 1726), the active metabolite of an approved antirheumatic drug Leflunomide, is an emerging oral therapy for multiple sclerosis (MS). Teriflunomide has demonstrated anti-inflammatory, antiproliferative and immunosuppressive
-
- Properties
-
Overview